Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fumitake Kai

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|March 11, 2014
[Incomplete self-castration by the patient with gender identify disorder: a case report]Fumitake Kai, Daisuke Motoyama, Toshiyuki Un-no, et al.
Japanese Journal of Clinical Oncology|May 14, 2013
Axitinib controlled metastatic renal cell carcinoma for 5 yearsTatsuya Takayama, Masao Nagata, Fumitake Kai, et al.
Medical Oncology (Northwood, London, England)|April 4, 2013
Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case studyTatsuya Takayama, Hiroshi Furuse, Fumitake Kai, et al.
Clinical and Experimental Nephrology|December 1, 2010
Natural history of renal cell carcinoma: a case with 18 years follow-upFumitake Kai, Tatsuya Takayama, Toshiki Ito, et al.
Cancer Investigation|April 14, 2017
Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1αRobert D Kendig, Fumitake Kai, Elizabeth A Fry, et al.
Hinyokika Kiyo. Acta Urologica Japonica|September 17, 2005
[Interferon-based cytokine therapy for advanced renal cell carcinoma]Tatsuya Takayama, Fumitake Kai, Takayuki Sugiyama, et al.
Japanese Journal of Clinical Oncology|April 14, 2009
Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy eraFumitake Kai, Tatsuya Takayama, Takayuki Sugiyama, et al.
International Journal of Molecular Sciences|October 30, 2020
Survival of Lung Cancer Patients Dependent on the LOH Status for <i>DMP1</i>, <i>ARF</i>, and <i>p53</i>Elizabeth A Fry, Gloria E Niehans, Robert A Kratzke, et al.
Japanese Journal of Clinical Oncology|April 19, 2011
Should ipsilateral solitary adrenal involvement in renal cell carcinoma be staged as M1?Tatsuya Takayama, Takayuki Sugiyama, Fumitake Kai, et al.
Clinical Medicine Insights. Oncology|June 23, 2010
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical SignificancePankaj Taneja, Dejan Maglic, Fumitake Kai, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|March 11, 2014
[Incomplete self-castration by the patient with gender identify disorder: a case report]Fumitake Kai, Daisuke Motoyama, Toshiyuki Un-no, et al.
Japanese Journal of Clinical Oncology|May 14, 2013
Axitinib controlled metastatic renal cell carcinoma for 5 yearsTatsuya Takayama, Masao Nagata, Fumitake Kai, et al.
Medical Oncology (Northwood, London, England)|April 4, 2013
Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case studyTatsuya Takayama, Hiroshi Furuse, Fumitake Kai, et al.
Clinical and Experimental Nephrology|December 1, 2010
Natural history of renal cell carcinoma: a case with 18 years follow-upFumitake Kai, Tatsuya Takayama, Toshiki Ito, et al.
Cancer Investigation|April 14, 2017
Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1αRobert D Kendig, Fumitake Kai, Elizabeth A Fry, et al.
Hinyokika Kiyo. Acta Urologica Japonica|September 17, 2005
[Interferon-based cytokine therapy for advanced renal cell carcinoma]Tatsuya Takayama, Fumitake Kai, Takayuki Sugiyama, et al.
Japanese Journal of Clinical Oncology|April 14, 2009
Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy eraFumitake Kai, Tatsuya Takayama, Takayuki Sugiyama, et al.
International Journal of Molecular Sciences|October 30, 2020
Survival of Lung Cancer Patients Dependent on the LOH Status for <i>DMP1</i>, <i>ARF</i>, and <i>p53</i>Elizabeth A Fry, Gloria E Niehans, Robert A Kratzke, et al.
Japanese Journal of Clinical Oncology|April 19, 2011
Should ipsilateral solitary adrenal involvement in renal cell carcinoma be staged as M1?Tatsuya Takayama, Takayuki Sugiyama, Fumitake Kai, et al.
Clinical Medicine Insights. Oncology|June 23, 2010
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical SignificancePankaj Taneja, Dejan Maglic, Fumitake Kai, et al.
Pageof 2